Smith & Nephew Plc (SNN) Q3 2024 Earnings Conference Call Transcript Summary
Smith & Nephew Plc (SNN) Q3 2024 Earnings Conference Call Transcript Summary
Under the 12-Point Plan, significant operational improvements have been noted, particularly in the U.S. Recon business which has grown due to improved product supply and commercial execution.The following is a summary of the Smith & Nephew Plc (SNN) Q3 2024 Earnings Conference Call Transcript:
以下是Smith & Nephew Plc（SNN）2024年第三季度業績會電話會議記錄摘要：
Financial Performance:
金融業績：
Smith & Nephew reported Q3 revenue of $1.4 billion, marking a 4% underlying growth.
Projected annual underlying revenue growth revised to 4.5%, with an anticipated trading margin expansion of up to 50 basis points.
Smith & Nephew報告了第三季度營業收入爲14億美元，標誌着基礎增長率爲4%。
預計年度基礎營收增長率修訂爲4.5%，預期交易利潤率將擴張至50個點子。
Business Progress:
業務進展：
Under the 12-Point Plan, significant operational improvements have been noted, particularly in the U.S. Recon business which has grown due to improved product supply and commercial execution.
Implementation of robotics and innovation in orthopedics, such as the new CATALYSTEM in hips and advancements in the EVOS plating system, are enhancing Smith & Nephew's product portfolio.
Advanced Wound Management experienced its best growth quarter, driven by increased adoption across regions and categories.
在12點計劃下，顯着的運營改進已經被注意到，特別是由於產品供應和商業執行的改善，美國Recon業務已經增長。
實施了機器人技術和在骨科領域的創新，例如新的CAELSTEm髖關節產品和EVOS骨板系統的進步，正在增強Smith & Nephew的產品組合。
愛文思控股的高級傷口管理業務經歷了其最佳增長季度，受到各地區和類別採用增加的推動。
Opportunities:
機會：
Growth momentum in established markets expected to continue with operational improvements and product innovations.
Advanced robotics and innovative products like CATALYSTEM hip systems and the EVOS plating system represent key growth drivers.
在成熟市場中，預計增長勢頭將繼續，通過運營改進和產品創新。
愛文思控股和CATALYSTEm髖部系統等創新產品代表關鍵的增長驅動力。
Risks:
風險：
Projected slower growth from the Sports Medicine Volume-Based Procurement (VBP) in China, along with delayed benefits from expected volume increases, likely contributing more to margin pressure in 2025.
Persistent underperformance and low order expectations in China's recon business impacting near-term growth prospects.
預計中國體育醫學成交量採購（VBP）的增長將放緩，加上預期成交量增加帶來的效益延遲，可能更多地導致2025年利潤壓力。
中國的重建業務持續表現不佳和訂單預期偏低，影響近期增長前景。
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：如需更全面的詳情，請參閱投資人關係網站。本文僅供投資者參考，不作任何指引或建議。
譯文內容由第三人軟體翻譯。
